Ocular implant made by a double extrusion process
The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
1. A bioerodible implant for treating a medical condition of the eye comprising a double extruded filament including a corticosteroid uniformly dispersed within a biodegradable polymer matrix, wherein the bioerodible implant exhibits a cumulative release profile in which greater than about 80 percent of the active agent is released about 28 days after implantation of the bioerodible implant, and wherein the cumulative release profile is approximately sigmoidal in shape over about 28 days after implantation.
2. The bioerodible implant of claim 1 wherein the corticosteroid is selected from the group consisting of cortisone, dexamethasone, fluocinolone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, and any derivative thereof.
3. The bioerodible implant of claim 2 wherein the corticosteroid comprises dexamethasone.
4. The bioerodible implant of claim 1 wherein the corticosteroid is about 10 to about 90 percent by weight of the bioerodible implant.
5. The bioerodible implant of claim 4 wherein the corticosteroid is about 60 percent by weight of the bioerodible implant.
6. The bioerodible implant of claim 1 wherein the biodegradable polymer matrix comprises a polyester.
7. The bioerodible implant of claim 6 wherein the biodegradable polymer matrix comprises poly(lactic-co-glycolic)acid (PLGA) copolymer.
8. The bioerodible implant of claim 7 wherein the ratio of lactic to glycolic acid monomers is about 50/50 weight percentage.